40
Vol. 66, No. 1 2015
Northeast Florida Medicine
Otolaryngology
26. Stavrakis AI, et al. Surgeon volume as a predictor of
outcomes in inpatient and outpatient endocrine sur-
gery.
Surgery
2007; 142: 887-899.
27. Yoo H, et al. Comparison of surgical outcomes be-
tween endoscopic and robotic thyroidectomy.
J Surg
Oncol
2012; 105:705-8.
28. Alexander EK, et al. Preoperative diagnosis of benign
thyroid nodules with indeterminate cytology.
N Engl J
Med
2012; 367:705-715.
29. Bonner JA, et al. Radiotherapy plus cetuximab for
squamous-cell carcinoma of the head and neck.
J. Engl
J Med
2006; 354:567-578.
30. Bonner JA, et al. Radiotherapy plus cetuximab for
locoregionally advanced HEAD AND NECK CAN-
CER: 5-year survival date from a phase 3 randomised
trial, and relation between cetuximab-induced rash
and survival.
The Lancet Oncology
2010; 11:21-28.
31. Wells SA Jr, et al. Vandetanib in patients with locally
advanced or metastatic medullary thyroid cancer: a
randomized, double-blind phase III trial.
J Clini Oncol
2012; 30:134-41.
32. Brose MS, et al. Sorafenib in radioactive iodine-refrac-
tory, locally advanced or metastatic differentiated thy-
roid cancer: a randomized, double-blind, phase 3 trial.
Lancet
. 2014 Apr 23. pii: S0140-6736(14)60421-9.
doi: 10.1016/S0140-6736(14)60421-9. [Epub ahead
of print]
33.
